Advantages of plasmatic CXCL-10 as a prognostic and diagnostic biomarker for the risk of rejection and subclinical rejection in kidney transplantation
Millán, O. ![ORCID Identifier](/img/uab/orcid.ico)
(Instituto de Salud Carlos III)
Rovira, J. (Red de Investigación Renal (REDINREN))
Guirado, Luis ![ORCID Identifier](/img/uab/orcid.ico)
(Institut d'Investigació Biomèdica Sant Pau)
Espinosa, C. (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Budde, K. (Charité - Universitätsmedizin Berlin)
Sommerer, Claudia ![ORCID Identifier](/img/uab/orcid.ico)
(Heidelberg University Hospital (Alemanya))
Piñeiro, G.J. (Institut Clínic de Nefrologia i Urologia. Servei de Nefrologia i Trasplantament Renal)
Diekmann, Fritz
(Institut Clínic de Nefrologia i Urologia. Servei de Nefrologia i Trasplantament Renal)
Brunet, M. (Instituto de Salud Carlos III)
Date: |
2021 |
Abstract: |
This study evaluate the potential of plasmatic CXCL-10 (pCXCL-10) as a pre&post transplantation prognostic and diagnostic biomarker of T-cell-mediated rejection (TCMR), antibody-mediated rejection (ABMR) and subclinical rejection (SCR) risk in adult kidney recipients considering BKV and CMV infections as possible clinical confounder factors. Twenty-eight of 100 patients included experienced rejection (TCMR:14; ABMR:14); 8 SCR; 13 and 16 were diagnosed with BKV and CMV infection, respectively. Pre-transplantation pCXCL-10 was significantly increased in TCMR and ABMR and post-transplantation in TCMR, ABMR and SCR compared with nonrejectors. All CMV patients showed pCXCL-10 levels above the cutoff values established for rejection whereas the 80% of BKV patients showed pCXCL-10 concentration < 100 pg/mL. pCXCL-10 could improve pre-transplantation patient stratification and immunosuppressive treatment selection according to rejection risk; and after kidney transplantation could be a potential early prognostic biomarker for rejection. Clinical confounding factor in BKV and particularly in CMV patients must be discarded. |
Note: |
Altres ajuts: Fundación Mutua Madrileña (AP153362014); TEVA Pharmaceuticals. |
Rights: |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades. ![Creative Commons](/img/licenses/by-nc-nd.ico) |
Language: |
Anglès |
Document: |
Article ; recerca ; Versió publicada |
Subject: |
Kidney transplantation ;
CXCL-10 ;
Rejection (TCMR ABMR SCR) ;
BKV ;
CMV ;
Biological matrix |
Published in: |
Clinical Immunology, Vol. 229 (august 2021) , p. 108792, ISSN 1521-7035 |
DOI: 10.1016/j.clim.2021.108792
PMID: 34217849
The record appears in these collections:
Research literature >
UAB research groups literature >
Research Centres and Groups (research output) >
Health sciences and biosciences >
Institut de Recerca Sant PauArticles >
Research articlesArticles >
Published articles
Record created 2023-02-03, last modified 2024-05-16